Loss in Medical Technology

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

... Isis also reported a pro forma net operating loss of $1.3 million for the second quarter compared ... forma net income and a pro forma net operating loss in the low to mid $20 million range, in both ... Results On a GAAP basis, Isis reported a loss from operations of $4.8 million and $5.5 million ...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

... second quarter ended June 30, 2009. Net loss for the quarter ended June 30, 2009 was $32.1 million or $0.35 per share, compared to net loss of $33.4 million or $0.36 per share in the second ... ------ ------ ------ ------- loss from operations (30,480) (33,358) ...

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)

... clinical trials testing the drug for bone loss and destruction associated with cancer treatment-induced bone loss in breast and prostate cancers, for the ... women, and treatment and prevention of bone loss in patients undergoing hormone ablation for ...

Is Your Hair Taking a Break?

... CAN HELP WOMEN GET TO THE ROOT OF HAIR loss BOSTON, July 29 /PRNewswire-USNewswire/ ... take years off of her appearance. That's why hair loss can be particularly devastating for women, and ... N.C., discussed the different types of hair loss women experience and the current treatment ...

Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study

... difference in weight, with a mean weight loss of 5.8 pounds at 26 weeks, compared with a mean ... significantly greater A1C reduction, weight loss versus weight gain and fewer episodes of ... considered obese.(v) Data indicate that weight loss (even a modest amount) supports patients in their ...

Prospective Clinical Advantages of Trabecular Metal(TM) Technology Highlighted in Comparative Study

... , found significant reductions in acetabular bone loss adjacent to the Trabecular Metal device ... over the course of 6 to 9 years and compared bone loss around highly porous Trabecular Metal cups ... certain areas of their implants, compared to a loss of up to 45% in BMD in certain areas of the ...

Reliv International's GlucAffect(TM) Proven Effective in Clinical Study

... Blood Glucose Levels and Promotes Weight loss CHESTERFIELD, Mo., July 16 ... blood sugar levels as well as significant weight loss compared to both their own baseline starting ... address essential daily nutrition, weight loss and targeted solutions such as energy and ...

Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases

... clinical trials testing the drug for bone loss and destruction associated with cancer treatment-induced bone loss in breast and prostate cancers, for the ... women, and treatment and prevention of bone loss in patients undergoing hormone ablation for ...

June 2009 Mayo Clinic Women's HealthSource Highlights Summer Skin Problems, Low Vision and Pilates

... people with low vision -- a permanent partial loss of eyesight that makes everyday tasks difficult. ... retinopathy or retinitis pigmentosa. Vision loss can be mild to severe. Patients should work ... regularly, Pilates can assist with weight loss and help alleviate low back pain. Pilates ...

Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients

... lining in the joints. This inflammation causes a loss of joint shape and function, resulting in pain, ... hands, feet, elbows, knees and neck that leads to loss of function. In addition, the systemic symptoms ... "no narrowing" and 4 representing "total loss of the joint space." Increases in the scores ...

Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily

... tadalafil) reported a sudden decrease or loss of vision or hearing, or in men, an erection ... hours. A patient who experiences a decrease or loss in vision or hearing or prolonged erection should ... (including CIALIS) reported a sudden decrease or loss of vision, or a sudden decrease ...

Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk

... significant categorical and absolute weight loss in Year 1, and continued treatment with ... significantly more patients maintain their weight loss as compared to those on placebo. Treatment with ... for placebo (p<0.0001). The average weight loss in this population was 17.9 pounds in the ...

Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients

... damage, which is a major cause of disability and loss of physical function for RA patients," said ... lining in the joints. This inflammation causes a loss of joint shape and function, resulting in pain, ... hands, feet, elbows, knees and neck that leads to loss of function. In addition, the systemic symptoms ...

Spherix Reports First Quarter 2009 Earnings

... first quarters ended 2009 and 2008. The net loss for the quarter ended March 31, 2009 was $2.0 million or $0.14 per share, compared with a net loss of $1.9 million or $0.13 per share for the same ... --------- --------- loss from operations ...

BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results

... professional fees and operating costs. Net loss for the quarter ended March 31, 2009, was $9.3 million, or $0.24 per share, compared to a net loss for the quarter ended March 31, 2008, of $13.1 ... 13,746 24,784 loss from operations (9,387) ...

Bionovo Announces First Quarter 2009 Highlights and Financial Results

... second quarter. The Company reported a net loss for the three months ended March 31, 2009 of $4.7 million, or $0.06 per share, compared with a net loss of $3.9 million, or $0.05 per share, for the same ... 4,610 4,209 47,331 loss from operations (4,610) ...

Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status

... an update on its product candidates. The net loss for the quarter, as reported in accordance with ... States (GAAP), was $6.9 million compared to a net loss of $18.4 million in the comparable period in ... 160, the Company no longer reverses from our net loss from operations the "Loss attributed to ...

Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity

... Study Results Demonstrated Significant Weight loss in Obese Patients Treated with Qnexa ... The Netherlands. The results, titled "Weight loss at 6 Months with VI-0521 Treatment," will be ... The phase 3 EQUATE trial evaluated weight loss achieved with two doses of Qnexa versus that ...

Study Reported Tadalafil Taken Once Daily Improved Erectile Function in Men with ED and Sexual Quality of Life in Couples

... (including Cialis) reported a sudden decrease or loss of vision, or a sudden decrease or loss of hearing (sometimes with ringing in the ears ... other factors. If a man has a sudden decrease or loss of vision or hearing, he should stop taking any ...

Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update

... Results The Company reported a net loss of $13.0 million ($0.38 diluted loss per share on a loss applicable to common shares of $13.1 million) for ...

Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion

... in the retina, resulting in retinal injury and loss of vision. The retina can also become "ischemic" ... new blood vessels that can cause further vision loss and more serious complications. The Phase 3 ... and there is no approved treatment to prevent the loss of vision or improve vision once it is lost," ...

Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results

... part by associated severance costs. Net loss Attributable to Lexicon Pharmaceuticals, Inc.: Net loss for the three months ended March 31, 2009 was $21.6 million, or $0.16 per share, compared to a net loss of $18.0 million, or $0.13 per share, in the ...

Pistachios Offer Protective Benefits Against Heart Disease, Type II Diabetes and Obesity

... part of a calorie-controlled, three-month weight loss diet. The researchers randomly assigned ... This is equivalent to about a 10-12 pound weight loss for most adults of average height. At the ... pistachios can be part of a successful weight loss program, and they provide the added benefits of ...

New Weight Loss Hope for People with Diabetes

... NutriSystem (Nasdaq: NTRI ), a leading weight loss program that delivers to your door, today announced the launch of new NutriSystem D, a weight loss program designed specifically for the ... a hospital-directed diet regimen. This weight loss was also associated with significant reductions ...

Pivotal Clinical Data Published for the Only Laser Phototherapy Device Cleared by the FDA for Hair Growth

... convenient, well-tolerated treatment for hair loss caused by Androgenic Alopecia in males." ... produces healthier hair, prevents further hair loss and stimulates the re-growth of thicker terminal ... the scalp into the hair follicles. Many hair loss sufferers now have newfound hope in their battle ...

Genetic Source of Rare Childhood Cancer Found; Gene is Implicated in Other Cancers

... model for understanding how mutations and loss of DICER1 function lead to cancer," says lead ... not previously demonstrated. They discovered that loss of DICER1 protein specifically in lung airway ... into malignant cells. However, the cells with the loss of DICER1 do not progress to malignancy. ...

Study Confirms: Your Hidden Food Allergies Are Making You Fat

... that patients unable to achieve goal weight loss by calorie restriction alone were significantly ... of the 12 week study, the 27 refractory weight loss patients underwent a single treatment: avoidance ... The study participants showed an average weight loss of approximately 37 pounds plus an average drop ...

Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study

... significant differences in weight, with weight loss of 6.2 pounds at 26 weeks, compared with a loss of 1.9 pounds for sitagliptin, and a weight gain ... A1C targets, with the added benefits of weight loss and no major hypoglycemia, could provide patients ...

Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years

... endpoint of the SPIRIT II trial was in-stent late loss at six months, wherein XIENCE V demonstrated ... significant 69 percent reduction in late loss (mean, 0.11 mm for XIENCE V vs. 0.36 mm for TAXUS). In-stent late loss is a measure of vessel re-narrowing. About ...

Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update

... Financial Results The Company reported a net loss of $13.9 million ($0.41 diluted loss per share on a loss applicable to common shares of $14.1 million) for ...

Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments

... with GSK. The Company reported a net loss for 2008 of $244.9 million ($1.81 per share), compared with a net loss of $262.4 million ($1.95 per share) for 2007. The decreased net loss for 2008 was due primarily to a gain on the sale ...

Staying One Step Ahead of Osteoporosis

... New studies show key steps to preventing bone loss focus on early screening and treatment LAS ... the rate of hip fractures saves lives, prevents loss of function, and decreases costs," said Tad ... D therapy is not enough to prevent further bone loss and fragility fractures in these patients." Men ...

American Academy Of Orthopaedic Surgeons 2009 Annual Meeting 'Highlights and Hot Topics'

... Surgery can be complicated by Sudden Cartilage loss ( ... Shoulder Arthroscopy Can Lead to Devastating loss After arthroscopic shoulder ... shoulder, a condition that results in complete loss of cartilage and secondary arthritis. A new study ...

Can Exercising Your Brain Prevent Memory Loss?

... percent decrease in the risk of developing memory loss compared to people who did not do those ... were 50 percent less likely to develop memory loss than people who watched for more than seven hours ... about 40 percent less likely to develop memory loss than those who did not do those activities. ...

Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)

... subjects has provided early indicators of weight loss and improved glucose control. These results ... models which demonstrated significant weight loss without metabolic rebound, which often limits sustained weight loss during caloric restriction. In addition, ...

Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent

... of the SPIRIT III trial was in-segment late loss at eight months, wherein XIENCE V demonstrated ... significant 50 percent reduction in late loss (mean, 0.14 mm for XIENCE V vs. 0.28 mm for TAXUS). In-segment late loss is a measure of vessel renarrowing. In the ...

Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia

... subjects has provided early indicators of weight loss and improved glucose control. These results ... models which demonstrated significant weight loss without metabolic rebound, which often limits sustained weight loss during caloric restriction. In addition, ...

Pharmasset Reports Fiscal Year End 2008 Financial Results

... during 2008. Pharmasset reported a net loss attributable to common stockholders of $54.7 million, or $2.51 per share, as compared to a net loss attributable to common stockholders of $6.8 ... 29,529,533 18,409,248 OPERATING loss (54,427,614) (7,520,075) ...

Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics

... linear PK, produced dose-dependent weight loss and improved insulin sensitivity. We expect the ... has produced consistent, sustainable weight loss in a variety of animal models and appears to ... readjustment, which often limits sustained weight loss during caloric restriction. In addition, ...

Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease

... U.S. alone). It is believed to be caused by a loss of nerve cells in the midbrain. The resulting symptoms include tremor, abnormal gait and posture, loss of balance, muscle stiffness and slowness of ... this stage, patients often experience periods of loss of movement control during the day (so-called ...